Funding for this research was provided by:
National Cancer Institute (P30 CA008748)
Article History
Received: 12 April 2019
Accepted: 29 May 2019
First Online: 16 July 2019
Compliance with ethical standards
:
: MSK has partnered with Y-mAbs Therapeutics to develop Omburtamab and has a financial contract with Y-mAbs Therapeutics. Dr. Kim Kramer is a consultant to Y-mAbs Therapeutics, Inc. Omburtamab was licensed to Y-mAbs Therapeutics in 2015. The clinical trial discussed was not sponsored by Y-mAbs Therapeutics.